TriSalus Life Sciences, Inc. TLSI
At closeNov 11, 2026, 4:56 PM EST
After hours · Nov 11, 4:56 PM ET
- YTD
- -67.05%
- 1 year
- -47.00%
- Market cap
- 141.91M
- Revenue (ttm)
- 24.74M
- Profit margin
- -219.71%
- EPS (ttm)
- -0.41
- Shares out
- 30.49M
- Forward P/E
- -3.50
- YTD return
- -67.05%
- 1-year return
- -47.00%
- Volume
- 913.31K
- Avg volume
- 270.08K
- Open
- 2.75
- Previous close
- 2.85
- Day's range
- 2.27 – 2.81
- 52-week range
- 2.20 – 7.95
- Beta
- 0.50
- Analysts
- Strong Buy
- Price target
- 11.64 (+406.2%)
- Earnings date
- Aug 14, 2024
5D -0.76 (-21.11%)
Key statistics
- Enterprise value
- 121.48M
- PEG ratio
- 0.00
- Price / sales
- 5.09
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 59.70%
- Free cash flow
- -52.96M
- Total cash
- 16.48M
- Total debt
- 22.76M
- Return on equity
- 0.00%
- Short % of float
- 0.32%
- 50-day average
- 4.14
- 200-day average
- 6.29
Analyst view
Consensus: strong buy
- Target (low)
- 10.00
- Target (mean)
- 11.64
- Target (high)
- 16.00
- Strong buy2
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.35.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.36 | -0.40 | -0.04 | -11.11% |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.21 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.54 | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | -1.56 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | Cantor Fitzgerald | init | — | Overweight |
| Nov 15, 2024 | Canaccord Genuity | main | Buy | Buy |
| Nov 11, 2024 | Roth MKM | init | — | Buy |
| Oct 25, 2024 | Northland Capital Markets | init | — | Outperform |
| Sep 16, 2024 | Oppenheimer | init | — | Outperform |
| Jun 27, 2024 | Canaccord Genuity | main | Buy | Buy |
About TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- trisaluslifesci.com
News
Canaccord Genuity Maintains Buy on TriSalus Life Sciences, Lowers Price Target to $4 
HC Wainwright & Co. Maintains Buy on TriSalus Life Sciences, Lowers Price Target to $10 
TriSalus Life Sciences Q3 Earnings Call Highlights 
TriSalus Life Sciences, Inc. (TLSI) Q3 2026 Earnings Call Transcript 
TriSalus Life Sciences Q3 2026 Earnings Call Transcript 
TriSalus Life Sciences Lowers FY2026 Sales Guidance from $54.000M-$57.000M to $46.000M-$48.000M vs $53.119M Est 
TriSalus Life Sciences Q3 EPS $(0.15) Misses $(0.13) Estimate, Sales $12.900M Miss $14.024M Estimate 
TriSalus Life Sciences Reports Third Quarter 2026 Results 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
Full Transcript: TriSalus Life Sciences Q2 2026 Earnings Call
Your note
Sign in to keep a note on TLSI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COX BRYAN F | Officer | Sale | Oct 3, 2024 | 86,382 |
| DESAI ARJUN JJ | Director | Sale | Dec 9, 2024 | 247,127 |
| FRANKENIUS EQUITY AB | Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 16, 2024 | 6,230,750 |
| KATZ STEVEN C. | Officer | Stock Award(Grant) | Feb 11, 2024 | 68,587 |
| MARSHAK RICHARD | Officer | Stock Award(Grant) | Nov 13, 2024 | 34,126 |
| MARTIN GEORGE KELLY | Director | Sale | Aug 27, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wealthcare Advisory Partners LLC | 2.11% | 643,740 | 2.66M | Sep 29, 2024 |
| Duquesne Family Office Llc | 1.40% | 426,921 | 1.76M | Sep 29, 2024 |
| Vanguard Group Inc | 1.36% | 416,138 | 1.72M | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.66% | 200,427 | 827.76K | Sep 29, 2024 |
| Millennium Management Llc | 0.32% | 97,888 | 404.28K | Sep 29, 2024 |
| Exos Asset Management LLC | 0.13% | 38,604 | 159.43K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.82% | 248,877 | 1.03M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.53% | 162,125 | 669.58K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.34% | 102,494 | 423.30K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.11% | 34,186 | 141.19K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.08% | 24,313 | 100.41K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.06% | 17,239 | 71.20K | Oct 30, 2024 |